REAL3 reanalysis gives insight into liquid biopsy and EGFR inhibition in stomach cancer

Written by Louis Gautier, Future Science Group

stomach cancer

A recent study from the Institute of Cancer Research (ICR) and the Royal Marsden Hospital (both London, UK) has reconsidered data from the REAL3 Phase III trial (published in 2013) to test the accuracy of liquid biopsy diagnosing EGFR mutations in stomach and esophageal cancers. The team also give insight into the combination of EGFR inhibitors with the chemotherapeutic, epirubicin, and why this leads to poorer survival outcomes than either drug used as monotherapy for any cancers. Liquid biopsy is a diagnostic technique used to detect tumor DNA circulating in the bloodstream and is less invasive than tissue biopsies, which...

To view this content, please register now for access

It's completely free